IL2RG and acute myeloid leukemia: Additionally, Rag2–/–Il2rg–/– mice receiving CD3-depleted human primary AML blasts and donor Tc from HLA-mismatched healthy donors and treated with sabatolimab showed improved survival (Figure 7, D and E).